Qingdao Baheal Medical INC. Total Assets
Qingdao Baheal Medical INC. total assets. Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) holds total assets worth CN¥8.57 Billion CNY (≈ $1.25 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Qingdao Baheal Medical INC. for the company's overall valuation and market capitalisation.
Total Assets of Qingdao Baheal Medical INC. (2018–2025)
Total assets of Qingdao Baheal Medical INC. from 2018 to 2025. This chart illustrates how Qingdao Baheal Medical INC.'s total assets have evolved over time, based on quarterly financial data. See Qingdao Baheal Medical INC. stock quote for real-time trading data and today's change.
Qingdao Baheal Medical INC. - Asset Composition Analysis
Qingdao Baheal Medical INC. Total Assets Breakdown (December 2025)
Qingdao Baheal Medical INC. total assets breakdown as of December 2025. Qingdao Baheal Medical INC.'s total assets of CN¥8.57 Billion consist of 70.5% current assets and 29.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 26.4% |
| Accounts Receivable | CN¥1.46 Billion | 18.0% |
| Inventory | CN¥895.57 Million | 11.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥227.52 Million | 2.8% |
| Goodwill | CN¥112.49 Million | 1.4% |
Asset Composition Trend (2018–2025)
This chart illustrates how Qingdao Baheal Medical INC.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Qingdao Baheal Medical INC. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Qingdao Baheal Medical INC.'s current assets represent 70.5% of total assets in 2025, a decrease from 82.1% in 2018.
- Cash Position: Cash and equivalents constituted 26.4% of total assets in 2025, down from 29.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 18.0% of total assets.
Qingdao Baheal Medical INC. Competitors by Total Assets
Key competitors of Qingdao Baheal Medical INC. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
China National Medicines Corp Ltd
SHG:600511
|
China | CN¥35.13 Billion |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
China | CN¥21.18 Billion |
|
TELES Informationstechnologien AG
XETRA:TLIK
|
Germany | €4.29 Million |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
|
Farmaceutica R
RO:RMAH
|
Romania | RON345.32 Million |
Qingdao Baheal Medical INC. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.43 | 1.56 | 1.67 |
| Quick Ratio | 1.18 | 1.31 | 1.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.84 Billion | CN¥1.86 Billion | CN¥1.68 Billion |
Qingdao Baheal Medical INC. - Advanced Valuation Insights
This section examines the relationship between Qingdao Baheal Medical INC.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.05 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | 14.1% |
| Total Assets | CN¥8.11 Billion |
| Market Capitalization | $2.01 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Qingdao Baheal Medical INC.'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Qingdao Baheal Medical INC.'s assets grew by 14.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual total assets of Qingdao Baheal Medical INC. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥8.11 Billion ≈ $1.19 Billion |
+14.05% |
| 2024-12-31 | CN¥7.11 Billion ≈ $1.04 Billion |
+10.83% |
| 2023-12-31 | CN¥6.42 Billion ≈ $939.08 Million |
+25.46% |
| 2022-12-31 | CN¥5.12 Billion ≈ $748.50 Million |
+11.13% |
| 2021-12-31 | CN¥4.60 Billion ≈ $673.55 Million |
+13.63% |
| 2020-12-31 | CN¥4.05 Billion ≈ $592.75 Million |
+18.10% |
| 2019-12-31 | CN¥3.43 Billion ≈ $501.93 Million |
+30.57% |
| 2018-12-31 | CN¥2.63 Billion ≈ $384.42 Million |
-- |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more